Open AccessTPD52L1-ROS1 Rearrangement as a New Acquired Resistance Mechanism to Osimertinib That Responds to Crizotinib in Combination With Osimertinib in Lung Adenocarcinoma
Author(s) -
Caihua Xu,
Dapeng Li,
Weiming Duan,
Min Tao
Publication year - 2020
Publication title -
jto clinical and research reports
Language(s) - English
Resource type - Journals
ISSN - 2666-3643
DOI - 10.1016/j.jtocrr.2020.100034
Subject(s) - osimertinib , crizotinib , t790m , lung cancer , adenocarcinoma , medicine , cancer research , oncology , cancer , ros1 , malignant pleural effusion
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom